A Comparative evaluation of in vitro anti‑inflammatory and antifungal activity of Ganoderma lucidum strains DARL-4 and MS-1

Abstract

Background: Ganoderma lucidum commonly known as Reishi is a lignicolous high value medicinal mushroom belonging to family Ganodermataceae. DARL-4 is an indigenous strain and MS-1 is an exotic Malaysian strain which is in vitro cultivated under sterile condition. The main aim of this study is a comparative evaluation of in vitro anti-inflammatory and antifungal activity of G. lucidum strains DARL-4 and MS-1. Materials and Methods: The hydroalcoholic extract of G. lucidum strains DARL-4 and MS-1 was screened for in vitro anti-inflammatory activity using inhibition of albumin denaturation technique at different concentration. Diclofenac (100 μg/ml) was used as standard reference drug. In vitro antifungal activity of hydroalcoholic extract of G. lucidum strains DARL-4 and MS-1 was evaluated by agar well diffusion method using Candida albicans as a fungal strain. Fluconazole was used as standard drug. Results and Discussion: The % inhibition of denaturation produced by hydroalcoholic extract of DARL-4 and MS-1 was comparable with that produced by diclofenac. MS-1 shows more significant anti-inflammatory activity than DARL-4. DARL-4 and MS-1 show moderate antifungal activity with a zone of inhibition of 19 ± 0.21and 21 ± 0.36 mm, respectively, as compared to the standard (fluconazole) having zone of inhibition of 30 ± 0.03 mm. Conclusion: MS-1 possesses more significant anti-inflammatory and antifungal activity as compared to DARL-4.